- Home
- CCEL vs UNCY Comparison
CCEL vs UNCY Comparison
Compare CCEL & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEL
- UNCY
- Stock Information
- Founded
- CCEL 1989
- UNCY 2016
- Country
- CCEL United States
- UNCY United States
- Employees
- CCEL N/A
- UNCY N/A
- Industry
- CCEL Managed Health Care
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- CCEL Health Care
- UNCY Health Care
- Exchange
- CCEL Nasdaq
- UNCY Nasdaq
- Market Cap
- CCEL 50.0M
- UNCY 58.7M
- IPO Year
- CCEL 1997
- UNCY 2021
- Fundamental
- Price
- CCEL $7.71
- UNCY $0.62
- Analyst Decision
- CCEL
- UNCY Strong Buy
- Analyst Count
- CCEL 0
- UNCY 4
- Target Price
- CCEL N/A
- UNCY $5.50
- AVG Volume (30 Days)
- CCEL 15.6K
- UNCY 1.0M
- Earning Date
- CCEL 04-14-2025
- UNCY 03-27-2025
- Dividend Yield
- CCEL 3.24%
- UNCY N/A
- EPS Growth
- CCEL N/A
- UNCY N/A
- EPS
- CCEL N/A
- UNCY N/A
- Revenue
- CCEL $31,838,476.00
- UNCY N/A
- Revenue This Year
- CCEL $3.97
- UNCY N/A
- Revenue Next Year
- CCEL $0.91
- UNCY N/A
- P/E Ratio
- CCEL N/A
- UNCY N/A
- Revenue Growth
- CCEL 1.95
- UNCY N/A
- 52 Week Low
- CCEL $4.47
- UNCY $0.20
- 52 Week High
- CCEL $9.50
- UNCY $1.80
- Technical
- Relative Strength Index (RSI)
- CCEL 48.98
- UNCY 51.79
- Support Level
- CCEL $7.26
- UNCY $0.57
- Resistance Level
- CCEL $8.20
- UNCY $0.65
- Average True Range (ATR)
- CCEL 0.54
- UNCY 0.05
- MACD
- CCEL -0.02
- UNCY 0.01
- Stochastic Oscillator
- CCEL 34.15
- UNCY 76.36
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from cellular processing and cryogenic storage and it derives revenue from processing and testing fees and storage segment.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.